Completed PHASE2 INTERVENTIONAL 1-arm NCT01929616

Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) (RegARd-C)

Regorafenib Assessment in Refractory Advanced Colorectal Cancer

Sponsor: Jules Bordet Institute

Conditions Advanced Chemorefractory Colorectal Adenocarcinoma

Interventions regorafenib

Updated 8 times since 2017 Last updated: Jun 21, 2019 Started: Aug 31, 2013 Primary completion: May 13, 2016 Completion: Jun 17, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Chemorefractory Colorectal Adenocarcinoma, this trial is completed. The trial is conducted by Jules Bordet Institute and has accumulated 8 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jul 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Apr 2019 — Jul 2019 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jules Bordet Institute

Data source: Jules Bordet Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antwerp, Belgium , Brussels, Belgium , Charleroi, Belgium , Ghent, Belgium , Kortrijk, Belgium , Liège, Belgium , Lobbes, Belgium , Mons, Belgium , Namur, Belgium , Ottignies, Belgium and 3 more locations